

Resource Summary Report

Generated by [NIF](#) on Sep 15, 2026

PSN1

RRID:CVCL_1644

Type: Cell Line

Proper Citation

RRID:CVCL_1644

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1644

Proper Citation: RRID:CVCL_1644

Description: Cell line PSN1 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Pancreatic adenocarcinoma

Defining Citation: [PMID:1764370](#), [PMID:3009377](#), [PMID:3778442](#), [PMID:11787853](#), [PMID:18380791](#), [PMID:20164919](#), [PMID:22460905](#), [PMID:25167228](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26216984](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:29444439](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:35839778](#)

Comments: Characteristics: Established from a frozen tumor that had been stored at -80 Celsius for 1.5 years and which has then been passaged into a nude mice., Population: Japanese., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: PSN1

Synonyms: PSN-1

Cross References: BTO:BTO_0005179, CLO:CLO_0008512, EFO:EFO_0006739, CLDB:cl3949, CLDB:cl3950, AddexBio:C0018013/4990, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610,

ATCC:CRL-3211, ATCC:CRM-CRL-3211, BioGRID_ORCS_Cell_line:483, BioSample:SAMN03481109, BioSample:SAMN10988384, cancercelllines:CVCL_1644, Cell_Model_Passport:SIDM00469, CGH-DB:182-1, CGH-DB:9281-4, ChEMBL-Cells:ChEMBL3307348, ChEMBL-Targets:ChEMBL614241, Cosmic:710867, Cosmic:716172, Cosmic:733176, Cosmic:808165, Cosmic:808504, Cosmic:910546, Cosmic:2434092, Cosmic-CLP:910546, DepMap:ACH-000320, ECACC:94060601, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:910546, GEO:GSM206537, GEO:GSM887521, GEO:GSM888603, GEO:GSM1374836, GEO:GSM1670353, IARC_TP53:945, ICLC:HTL97008, LiGeA:CCLE_595, LINCS_LDP:LCL-1749, PharmacDB:PSN1_1277_2019, PRIDE:PXD030304, Progenetix:CVCL_1644, PubChem_Cell_line:CVCL_1644, Wikidata:Q54948596

ID: CVCL_1644

Record Creation Time: 20220427T221444+0000

Record Last Update: 20260913T005829+0000

Ratings and Alerts

No rating or validation information has been found for PSN1.

No alerts have been found for PSN1.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 32 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Miyahara S, et al. (2026) Exosomal microRNA-4800-3p in portal vein blood promotes liver metastasis in pancreatic cancer by targeting PLAA. Scientific reports, 16(1).

Kamgar M, et al. (2026) Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma. Cancer research, 86(8), 2042.

Sekiguchi N, et al. (2026)

Circ72309 modulates gemcitabine metabolism and gemcitabine sensitivity in pancreatic cancer: Serum Circ72309 levels as a potential predictor of treatment response

. International journal of oncology, 68(3).

Sun W, et al. (2026) Reconstruction of T cell infiltration in an osteosarcoma PDX-organoid interactive biobank for personalized immunotherapy. Cell reports. Medicine, 7(3), 102644.

Gong D, et al. (2026) GLIS3 marks a neural-like progenitor cell state that drives metastasis in pancreatic ductal adenocarcinoma. *Cell reports*, 45(5), 117314.

Manoukian P, et al. (2026) Estrogen Production in Pancreatic Cancer Shapes a Tumor-Suppressive Stromal Microenvironment. *Cancer research*, 86(3), 571.

Burge RA, et al. (2026) KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment. *Cancer research*, 86(8), 1868.

Maki R, et al. (2025) Efficacy of SOAT1 Inhibitors Against Pancreatic Cancer with TP53 Mutations. *Annals of surgical oncology*, 32(9), 7025.

Tang J, et al. (2025) CD44 identified as a diagnostic biomarker for highly malignant CA19-9 negative pancreatic cancer. *Cancer letters*, 622, 217713.

Toure MA, et al. (2025) Targeted degradation of CDK9 potentially disrupts the MYC-regulated network. *Cell chemical biology*, 32(4), 542.

Burge RA, et al. (2025) PTEN Oxidation Promotes Constitutive PI3K Signaling and Inducible Macropinocytosis in Pancreatic Cancer. *Cancer research*, OF1.

Gong D, et al. (2025) Integrated spatial morpho-transcriptomics predicts functional traits in pancreatic cancer. *Science advances*, 11(42), eadx0632.

Zhao B, et al. (2025) PLK1 blockade enhances the anti-tumor effect of MAPK inhibition in pancreatic ductal adenocarcinoma. *Cell reports*, 44(4), 115541.

Feng J, et al. (2025) A pan-KRAS inhibitor and its derived degrader elicit multifaceted anti-tumor efficacy in KRAS-driven cancers. *Cancer cell*.

Jeong J, et al. (2025) NSD2 inhibitors rewire chromatin to treat lung and pancreatic cancers. *Nature*.

Wittenzellner K, et al. (2025) Label-free single-cell phenotyping to determine tumor cell heterogeneity in pancreatic cancer in real time. *JCI insight*, 10(13).

Wang S, et al. (2025) IFN- γ -driven UBE2D3 upregulation impairs antigen presentation pathways and anti-tumor immunity in pancreatic cancer. *Nature communications*, 16(1), 10733.

Dorji JP, et al. (2025) c-MYC mRNA destabilization inhibited lethal pancreatic cancer in vivo with significant survival outcomes. *Frontiers in pharmacology*, 16, 1630476.

Hang H, et al. (2025) SP1-Mediated Glycolytic Reprogramming Promotes Tumorigenesis and Progression in Pancreatic Cancer. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, e10071.

Drizyte-Miller K, et al. (2025) Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Cancer. *Cancer research*, 85(18), 3540.